Quantum-Si incorporated

Quantum-Si incorporated (QSI) Market Cap

Quantum-Si incorporated has a market capitalization of $140.9M.

Price: $0.71

-0.01 (-1.06%)

Market Cap: 140.93M

NASDAQ · time unavailable

CEO: Jeffrey Alan Hawkins

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2020-11-13

Website: https://www.quantum-si.com

Quantum-Si incorporated (QSI) - Company Information

Market Cap: 140.93M|Sector: Healthcare

Company Profile

Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing processes. The company offers a unique, proprietary single molecule detection system that draws on advancements from the semiconductor industry. This system is specifically applied to the field of proteomics, paving the way for next-generation protein sequencing. Established in 2013, Quantum-Si's headquarters are located in Guilford, Connecticut.

Analyst Sentiment

82%
Strong Buy

From 3 Active Polls

1Y Forecast: $1.00

▲ +40.4% Potential Upside

Consensus Target Metrics

Low Bound

$1

Median

$1

High Bound

$1

Average

$1

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$1.00
▲ +40.37% Upside
Low Target
$1.00
40% Risk
Median Target
$1.00
40% Mid
High Target
$1.00
40% Max
Consensus
Buy
1 / 2 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)141168218295360219395126133
Enterprise Value ($M)1081352002683491943599787
Price to Earnings Ratio (P/E)-1.39-1.94-3.27-2.07-3.06-2.73-2.93-1.23-1.46
Price/Earnings-to-Growth Ratio (PEG)-0.06-0.05-0.04
Price to Sales Ratio (P/S)76.10649.42482.35533.96608.98259.81331.45159.62213.23
Price to Book Ratio (P/B)0.770.830.991.251.630.891.830.600.57
Price to Free Cash Flow Ratio (P/FCF)-1.47-6.46-13.32-8.95-17.54-7.97-16.25-5.21-6.74
Enterprise Value to Sales (EV/Sales)523.49443.61486.32590.29229.84301.00123.48139.42
Enterprise Value to EBITDA (EV/EBITDA)-1.18-5.92-10.04-11.56-13.64-8.00-11.17-4.03-3.99
Debt to Equity Ratio0.350.020.020.020.050.050.060.070.06

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 QUANTUM SI INC CLASS A (QSI) — Investment Overview

🧩 Business Model Overview

Quantum Si Inc. is positioned in the quantum computing and quantum technology value chain—developing specialized quantum hardware and the enabling tooling required to operate it. The path to commercialization typically runs through (1) proving technical performance (stability, scalability, and error characteristics), (2) integrating with customer workflows via software interfaces and system engineering, and (3) converting early partner collaborations into repeatable access arrangements or system deliveries.

In practical terms, the customer “value” emerges from whether QSI’s quantum systems can execute economically useful workloads (optimization, simulation, and sensing-related primitives) with performance that is competitive enough to justify experimentation through a structured adoption funnel.

💰 Revenue Streams & Monetisation Model

For companies in this stage of the quantum stack, monetization generally combines a mix of:

  • Research and development collaborations (partner-funded work, government/agency support where applicable).
  • Professional services and engineering support tied to system integration, benchmarking, and deployment of experimental workflows.
  • Prototype or system-related revenue when hardware deliveries and performance validation progress.
  • Potential future recurring revenue through access models (usage-based or subscription-like access to quantum capacity) if QSI’s systems reach operational maturity.

Margin structure is heavily dependent on technical progress. In quantum hardware, cost of revenue is typically driven by precision fabrication, cryogenic or control infrastructure (where relevant), and systems engineering. Over time, scale potential may improve if QSI transitions from bespoke prototypes toward standardized platforms and repeatable deployment models.

🧠 Competitive Advantages & Market Positioning

The core moat for QSI is best framed as intangible asset depth and technical execution: proprietary approaches to qubit implementation, device engineering, control methodology, and the accumulated know-how embedded in designs and operating procedures. In quantum computing, that know-how is difficult to replicate quickly because it depends on specialized engineering iteration and experimental learning cycles.

A secondary, potential moat is emerging switching costs. As customers integrate quantum workflows—calibration routines, algorithm tuning, and benchmarking artifacts—migrating off a given hardware platform can involve non-trivial revalidation effort. This switching cost tends to materialize only after sustained performance leadership and meaningful customer usage.

  • IonQ — emphasized around trapped-ion based quantum computing.
  • Rigetti — emphasized around superconducting approaches.
  • D-Wave — emphasized around quantum annealing / specialized optimization-focused architectures.

Industry focus contrast: QSI’s differentiation versus these competitors is primarily the underlying qubit/platform implementation and the implied engineering path to scale and error performance. While IonQ and Rigetti target broad programmable quantum computing via distinct physical qubit modalities, and D-Wave targets optimization-centric quantum annealing, QSI’s competitive position hinges on demonstrating performance and scalability in its chosen silicon-based platform strategy—thereby potentially selecting a different application fit and adoption curve.

🚀 Multi-Year Growth Drivers

  • Secular demand for quantum advantage: enterprise experimentation and research budgets expand as quantum systems move from demonstrations toward problem classes where performance is competitive.
  • Ecosystem build-out: growing partnerships across hardware, software tooling, and algorithm developers increase the “activation energy” required for new entrants—raising the importance of execution and integration capability.
  • Systems maturity milestones: the market for quantum compute (and adjacent sensing use cases) becomes investable when reliability, operational stability, and throughput improve enough to support repeated benchmarking and application trials.
  • TAM expansion across workflows: quantum use cases broaden beyond one niche category into simulation, optimization, and sensing-adjacent tasks—expanding total addressable demand if practical performance improves.

Over a 5–10 year horizon, the most durable value creation typically follows the company that can translate technical progress into a credible, repeatable path to customer adoption—moving from one-off experiments to structured access and integration.

⚠ Risk Factors to Monitor

  • Technical execution risk: quantum platforms face long-duration scaling challenges (error mitigation, stability, and system-level performance). Failure to achieve performance thresholds can delay monetization.
  • Competitive pace: competing qubit modalities can reach operational milestones faster, capturing ecosystem mindshare and partner relationships.
  • Capital intensity and dilution: hardware development and validation require sustained funding; insufficient runway can force equity issuance, diluting holders.
  • Commercialization uncertainty: even with hardware progress, customer adoption depends on application readiness, workflow integration, and demonstrable business value.
  • Export controls and regulatory constraints: quantum technologies can be subject to jurisdiction-specific controls affecting global customer reach and partnership structure.

📊 Valuation & Market View

Quantum-related companies are typically valued with a technology-stage framework rather than mature-industry multiples. The market often anchors on:

  • Platform progress indicators (performance and reliability milestones that influence probability-weighted commercialization).
  • Liquidity and financing outlook (cash runway and funding path given R&D intensity).
  • Path-to-revenue credibility (evidence of repeatable customer engagement, integration traction, and conversion from pilots to paid arrangements).

When businesses show strengthening commercial signals, valuation tends to shift toward forward revenue potential; when technical milestones slip or funding risk rises, valuation typically compresses regardless of long-term narrative.

🔍 Investment Takeaway

Quantum Si’s investment case rests on whether its platform can convert proprietary quantum engineering into operational performance that customers can repeatedly use and integrate. The primary economic advantage is intangible technology depth and the associated execution learning curve, with emerging switching costs forming only if the systems become sufficiently reliable and application-ready. For investors, the central question is not the ambition of quantum compute, but the probability-weighted trajectory from technical milestones to sustained, monetizable adoption.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for QSI.

globenewswire.com2026-07-27

Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026

BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the second quarter 2026 on Thursday, August 13, 2026.

businesswire.com2026-06-16

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

businesswire.com2026-06-10

Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™.

gurufocus.com2026-06-03

Quantum-Si Announces the Expansion of the Proteus™ Roadshow

[url="]Quantum-Si Incorporated[/url] (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analy

businesswire.com2026-06-03

Quantum-Si Announces the Expansion of the Proteus™ Roadshow

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Expansion of the Proteus™ Roadshow.

businesswire.com2026-05-27

euNetworks launches new quantum-safe private connectivity service powered by Adtran's encrypted optical transport technology

LONDON--(BUSINESS WIRE)-- #5G--Adtran and euNetworks today announced their collaboration on the launch of a new quantum-safe private connectivity service, Quantum Shield. euNetworks has developed Quantum Shield using Adtran's optical transport technology to augment its broader architecture, which is designed to deliver secure, scalable data center connectivity across euNetworks' pan-European network. The new offering is built for enterprises with stringent security, performance and customer-controlle.

seekingalpha.com2026-05-15

Quantum-Si incorporated (QSI) Shareholder/Analyst Call Prepared Remarks Transcript

Quantum-Si incorporated (QSI) Shareholder/Analyst Call Prepared Remarks Transcript

gurufocus.com2026-05-13

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

[url="]Quantum-Si Incorporated[/url] (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through

businesswire.com2026-05-13

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

marketbeat.com2026-05-08

Quantum-Si Q1 Earnings Call Highlights

Quantum-Si NASDAQ: QSI reported first-quarter 2026 revenue of $258,000 and reiterated that the year will be a transition period focused on development and market preparation for its next-generation Proteus protein sequencing platform.

zacks.com2026-05-07

Quantum-Si Incorporated (QSI) Reports Q1 Loss, Misses Revenue Estimates

Quantum-Si Incorporated (QSI) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.11 per share a year ago.

businesswire.com2026-05-07

Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones.

businesswire.com2026-05-01

Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference.

businesswire.com2026-04-28

Quantum-Si Announces Successful Sequencing on Integrated Proteus™ Instruments

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Successful Sequencing on Integrated Proteus™ Instruments.

investorplace.com2026-04-25

Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard

The real brain computer interface opportunity isn't in the headlines. These 10 stocks are building the systems that make it possible.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"QSI reported Q1’26 (ended 2026-03-31) revenue of $0.258M and net income of -$21.7M (EPS -$0.10). Revenue rose QoQ versus Q4’25 ($0.451M to $0.258M is a QoQ decline), and versus Q1’25 ($0.842M) revenue declined sharply. Net loss widened materially: net income of -$21.7M vs -$17.6M in Q4’25 (QoQ deterioration) and vs -$19.2M in Q1’25 (YoY deterioration). Gross margin improved sequentially from deeply negative in Q4’25 (-9.6%) to +28.7% in Q1’26, but the company remains unprofitable with operating margin around -93.2%. Cash flow remains negative: operating cash flow was -$25.6M and free cash flow -$25.9M. The company ended the quarter with $36.2M cash and $91.1M short-term investments (cash + ST investments $127.3M), with net debt remaining negative (net cash position). There were no dividends, and buybacks were not reported, so shareholder returns are driven by price action. With 1-year price change of -7.76% and no stated yield, total shareholder return momentum appears weak. Over the last 4 quarters, profitability has not stabilized, and losses are substantial relative to revenue."

Revenue Growth

Neutral

Revenue was $0.258M in Q1’26, down sharply YoY from $0.842M (about -69.4%). QoQ revenue also declined versus Q4’25 ($0.451M to $0.258M, about -42.8%), indicating a weakening sales trajectory.

Profitability

Neutral

Net income was -$21.7M in Q1’26, worse than Q4’25 (-$17.6M; about -23.0% more negative) and worse than Q1’25 (-$19.2M; about -12.8% more negative). Gross margin improved QoQ (from -9.6% in Q4’25 to +28.7% in Q1’26), but operating and net margins remain deeply negative (operating margin ~-93.2%).

Cash Flow Quality

Neutral

Operating cash flow was -$25.6M and free cash flow -$25.9M in Q1’26, with persistent quarterly cash burn. No dividends were paid and buybacks are not evident in the provided cash flow, so cash preservation is critical.

Leverage & Balance Sheet

Fair

Balance sheet shows resilience with a net cash position (net debt -$32.5M at 2026-03-31). Total assets were $213.3M, and total equity was $200.7M, which supports near-term solvency despite losses.

Shareholder Returns

Neutral

1-year price performance was -7.76% and dividend yield is 0%. With no buyback information provided, total shareholder returns appear negative and momentum is weak versus a +20% benchmark.

Analyst Sentiment & Valuation

Neutral

Consensus price target metrics are not meaningfully informative here (target values provided as $1), and the stock trades near $1.07 in the price data, offering limited upside signal. With sustained losses and negative cash flow, valuation support appears fragile.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

QSI’s Q1 2026 update is dominated by a transition-year setup for Proteus commercial launch in 2026, with near-term results constrained by customer purchase timing. On the performance side, management emphasized a key de-risking milestone: fully integrated Proteus sequencing with automated end-to-end workflows, plus measurable progress in sequencing chemistry (17 amino acids detected, up from 15 in Dec 2025) and expectations to reach 18 by 2026 and all 20 amino acids during 2026. Commercial preparation is focused on market education (Proteus roadshow series) and building a customer evaluation funnel rather than scaling capital sales immediately. Financially, the company reported $258k revenue with 29% gross margin driven by consumables mix; operating expenses declined year over year, and cash remains substantial at $190.4M. The main execution risk shifted from innovation to systems engineering, manufacturing transfer, and reliability/MTBF through the next ~six months.

AI IconGrowth Catalysts

  • Proteus development milestone: successful completion of sequencing on fully integrated Proteus instruments using automated end-to-end sequencing (reagent preparation through sequencing, data capture, analysis)
  • Proteus technical performance trajectory: developmental sequencing kit detection of 17 amino acids; increased unique amino acids from 15 (Dec 2025) to 17 in ~4 months
  • Proteus application expansion expected from higher proteome coverage (signal-to-noise, ability to detect shorter recognizer pulses; longer average peptide read lengths)
  • Post-translational modification (PTM) pathway progress: kinetic-signature-based PTM detection concept positioned as scalable vs affinity/mass-spec; more updates expected “near future”

Business Development

  • Customer engagement for Proteus prototype evaluation: existing Platinum user; customer sent samples for Proteus prototype sequencing vs Platinum (improvement validated via increased amino acids detected and longer average read length)
  • Customer data commercialization plan: first-generation Platinum instrument + commercially available kits used to generate posters (industry conferences) and manuscripts (preprint/peer-reviewed); referenced output since start of 2026 (3 manuscripts, 5 posters, 1 US HUPO podium)

AI IconFinancial Highlights

  • Q1 2026 revenue: $258k (Platinum instruments, consumable kits, related services); gross margin 29% driven primarily by consumables mix vs hardware
  • Management reiterated 2026 near-term revenue pressure due to Proteus launch timing (customers shifting purchasing decisions closer to Proteus availability)
  • Operating expense (2026): GAAP total operating expenses $24.1M vs $25.6M prior-year; adjusted operating expenses $21.4M vs $22.9M prior-year quarter
  • 2026 cash balance as of 03/31/2026: $190.4M cash/cash equivalents/investments in marketable securities
  • 2026 outlook (company guidance): total revenue ~ $1M; adjusted operating expenses ~$98M or less; expected cash usage ~$93M or less
  • Dividend and interest income: $1.9M in 2026 vs $2.5M prior-year quarter (lower interest rates and invested balance changes)

AI IconCapital Funding

  • No buyback disclosed in the provided transcript
  • Cash runway: company expects cash to support operations into 2028 (about ~1.5 years after estimated Proteus launch date)
  • Inventory/capex posture: modest inventory build and commercial readiness efforts included in expected cash usage

AI IconStrategy & Ops

  • 2026 characterized as a transition year: revenue driven by consumable utilization from installed base, modest new Platinum placements, and very modest new capital sales
  • Proteus launch readiness: focus on preserving financial strength with fiscal discipline while funding core strategic initiatives
  • Embedded upgrade paths in certain Platinum Pro unit sales in 2026 (near-term revenue impact)
  • Manufacturing approach: focus on ramping delivery of instruments for R&D first; inventory build for launch to be paced later in the year based on funnel/preorders
  • Roadshow program: Proteus roadshow series started; events generally 2 hours, designed for education (not hands-on training); customers expected to begin evaluation via sample submissions/data sharing

AI IconMarket Outlook

  • Near-term/operational milestones: early access program anticipated to begin in summer; early access sites expected to be “a handful” (not 10), spanning market segments/geographies
  • Proteus capability targets reiterated: confidence to deliver Proteus by 2026 with detection of 18 amino acids; detection of all 20 amino acids during 2026; sequencing kit in 2027 detecting all 20 amino acids
  • Guidance horizon: 2026 projected revenue ~ $1M with OpEx ~$98M or less and cash usage ~$93M or less; cash runway into 2028

AI IconRisks & Headwinds

  • Near-term revenue uncertainty from customer decision timing: customers may delay Platinum purchases until closer to Proteus availability
  • Execution risk on systems engineering/systems integration through the next ~6 months (reliability, precision, mean time between failures) even though “innovation breakthrough” is described as complete
  • Manufacturing and supply-chain ramp dependence: instrument build relies on third-party partners; inventory build for launch expected later in year, implying demand-related timing sensitivity
  • R&D and OpEx are described as “lumpy” quarter-to-quarter due to deployment with third-party partners

Q&A: Analyst Interest

  • Customer experience vs Platinum: Management framed Proteus benefits across three application buckets—protein identification, PTMs, and protein variants—explaining that higher amino-acid coverage and longer read lengths improve fidelity by capturing events distributed along peptide length, enabling broader application performance vs Platinum.
  • Operational gating into launch + volume outlook: Analysts asked whether gating factors are technological or primarily production/inventory. Management said the “invention/big breakthrough” is behind them; focus is manufacturing transfer, bring-up, reliability/MTBF, precision, and systems integration. They expect Proteus to increase utilization within Platinum and open new segments, but could not quantify multiplier.
  • Early access program design + execution planning: Asked about roadshows and early-access sites, including HQ training. Management said roadshows are educational (~2 hours) and not hands-on; they will drive sample evaluations via internal fleet. Early access sites should span segments/geographies; “at least a handful” active by end of summer.

Sentiment: MIXED

Note: This summary was synthesized by AI from the QSI Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for QSI.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (QSI)

© 2026 Stock Market Info — Quantum-Si incorporated (QSI) Financial Profile